Moreover, the various potencies in the identified effects are likely caused by the difference in the concentrations of CML adducts identified between the mixed AGE-HSA and pure CML-HSA preparations. The gene discussed is ALB; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.